# A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

> **NCT05070858** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 288 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** Pozelimab + Cemdisiran
- **DRUG:** Cemdisiran
- **OTHER:** Placebo
- **DRUG:** Pozelimab

## Key facts

- **NCT ID:** NCT05070858
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2025-07-08
- **Final completion:** 2028-11-11
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070858, "A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05070858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*